Operaciones ALX Oncology Holdings Inc. - ALXO CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Diferencial | 0.05 | ||||||||
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.024874% | ||||||||
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.002651% | ||||||||
Horario tarifa nocturna | 21:00 (UTC) | ||||||||
Cantidad comercializada mínima | 1 | ||||||||
Divisa | USD | ||||||||
Margen | 20% | ||||||||
Mercado de valores | United States of America | ||||||||
Comisión por operación | 0% |
*Information provided by Capital.com
Cierre previo* | 4.97 |
Abrir* | 4.95 |
Cambio de 1 año* | -73.17% |
Rango del día* | 4.43 - 5.01 |
Rango de 52 semanas | 4.52-19.85 |
Volumen medio (10 días) | 362.10K |
Volumen medio (3 meses) | 4.84M |
Capitalización de mercado | 203.78M |
Ratio P/E | -100.00K |
Acciones en circulación | 40.86M |
Ingresos | N/A |
EPS | -3.03 |
Dividendo (Rendimiento %) | N/A |
Beta | -100.00K |
Próxima fecha de resultados | May 8, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Cierre | Change | Change (%) | Apertura | High | Low |
---|---|---|---|---|---|---|
Mar 30, 2023 | 4.53 | -0.37 | -7.55% | 4.90 | 5.03 | 4.41 |
Mar 29, 2023 | 4.97 | 0.12 | 2.47% | 4.85 | 5.03 | 4.78 |
Mar 28, 2023 | 4.83 | 0.04 | 0.84% | 4.79 | 5.03 | 4.77 |
Mar 27, 2023 | 4.96 | 0.36 | 7.83% | 4.60 | 5.02 | 4.52 |
Mar 24, 2023 | 4.63 | -0.13 | -2.73% | 4.76 | 4.84 | 4.54 |
Mar 23, 2023 | 4.83 | 0.29 | 6.39% | 4.54 | 4.87 | 4.54 |
Mar 22, 2023 | 4.78 | -0.04 | -0.83% | 4.82 | 4.95 | 4.63 |
Mar 21, 2023 | 4.79 | 0.09 | 1.91% | 4.70 | 5.02 | 4.68 |
Mar 20, 2023 | 4.60 | -0.16 | -3.36% | 4.76 | 4.78 | 4.49 |
Mar 17, 2023 | 4.76 | -0.15 | -3.05% | 4.91 | 4.95 | 4.63 |
Mar 16, 2023 | 4.98 | -0.08 | -1.58% | 5.06 | 5.13 | 4.92 |
Mar 15, 2023 | 5.17 | 0.09 | 1.77% | 5.08 | 5.38 | 4.67 |
Mar 14, 2023 | 5.23 | -0.49 | -8.57% | 5.72 | 5.74 | 5.07 |
Mar 13, 2023 | 5.60 | 0.42 | 8.11% | 5.18 | 5.90 | 5.18 |
Mar 10, 2023 | 5.36 | -0.33 | -5.80% | 5.69 | 5.73 | 5.02 |
Mar 9, 2023 | 5.84 | -0.27 | -4.42% | 6.11 | 6.19 | 5.60 |
Mar 8, 2023 | 6.21 | -0.16 | -2.51% | 6.37 | 6.39 | 6.11 |
Mar 7, 2023 | 6.37 | 0.07 | 1.11% | 6.30 | 6.54 | 6.29 |
Mar 6, 2023 | 6.44 | -0.04 | -0.62% | 6.48 | 6.48 | 6.20 |
Mar 3, 2023 | 6.50 | 0.19 | 3.01% | 6.31 | 6.67 | 6.31 |
ALX Oncology Holdings Inc. Events
Hora (UTC) (UTC) | País | Evento |
---|---|---|
No events scheduled |
- Anual
- Trimestral
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Ingresos totales | 0 | 0 | 1.182 | 4.796 | 2.067 |
Ingresos | 0 | 0 | 1.182 | 4.796 | 2.067 |
Coste de los ingresos, total | 0 | 1.075 | 4.36 | 1.88 | |
Beneficio bruto | 0 | 0.107 | 0.436 | 0.187 | |
Gastos totales de explotación | 127.436 | 83.555 | 45.466 | 23.979 | 15.751 |
Gastos de venta/general/administración Gastos, total | 29.036 | 23.385 | 14.809 | 3.313 | 2.601 |
Investigación y desarrollo | 98.4 | 60.17 | 28.961 | 16.306 | 11.27 |
Ingresos de explotación | -127.436 | -83.555 | -44.284 | -19.183 | -13.684 |
Ingresos por intereses (gastos), netos No operativos | 4.278 | -0.013 | -0.811 | -0.021 | 0 |
Otros, netos | -0.26 | 0.084 | -0.404 | -0.005 | -0.002 |
Ingresos netos antes de impuestos | -123.418 | -83.484 | -45.499 | -19.209 | -13.686 |
Ingresos netos después de impuestos | -123.482 | -83.463 | -45.74 | -19.243 | -13.731 |
Beneficio neto antes de partidas extra. Elementos | -123.482 | -83.463 | -45.74 | -19.243 | -13.731 |
Ingresos netos | -123.482 | -83.463 | -45.74 | -19.243 | -13.731 |
Total Adjustments to Net Income | 0 | 0 | -5.202 | -4.028 | -3.671 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -123.482 | -83.463 | -50.942 | -23.271 | -17.402 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -123.482 | -83.463 | -50.942 | -23.271 | -17.402 |
Beneficio neto diluido | -123.482 | -83.463 | -50.942 | -23.271 | -17.402 |
Promedio ponderado de acciones diluidas | 40.6996 | 40.308 | 18.4853 | 34.7116 | 34.7116 |
BPA diluido sin partidas extraordinarias | -3.03398 | -2.07063 | -2.7558 | -0.67041 | -0.50133 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
BPA normalizado diluido | -3.03398 | -2.07063 | -2.73397 | -0.67041 | -0.50133 |
Gastos (ingresos) extraordinarios | 0 | 0 | 0.621 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Ingresos totales | 0 | 0 | 0 | 0 | 0 |
Ingresos | 0 | ||||
Gastos totales de explotación | 32.219 | 36.681 | 33.789 | 24.747 | 28.472 |
Gastos de venta/general/administración Gastos, total | 7.022 | 7.299 | 7.041 | 7.674 | 7.578 |
Investigación y desarrollo | 25.197 | 29.382 | 26.748 | 17.073 | 20.894 |
Ingresos de explotación | -32.219 | -36.681 | -33.789 | -24.747 | -28.472 |
Ingresos por intereses (gastos), netos No operativos | 1.807 | 1.37 | 0.876 | 0.225 | -0.003 |
Otros, netos | -0.233 | -0.009 | -0.007 | -0.011 | 0.016 |
Ingresos netos antes de impuestos | -30.645 | -35.32 | -32.92 | -24.533 | -28.459 |
Ingresos netos después de impuestos | -30.709 | -35.32 | -32.92 | -24.533 | -28.438 |
Beneficio neto antes de partidas extra. Elementos | -30.709 | -35.32 | -32.92 | -24.533 | -28.438 |
Ingresos netos | -30.709 | -35.32 | -32.92 | -24.533 | -28.438 |
Total Adjustments to Net Income | 0 | ||||
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -30.709 | -35.32 | -32.92 | -24.533 | -28.438 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -30.709 | -35.32 | -32.92 | -24.533 | -28.438 |
Beneficio neto diluido | -30.709 | -35.32 | -32.92 | -24.533 | -28.438 |
Promedio ponderado de acciones diluidas | 40.7459 | 40.747 | 40.6878 | 40.6163 | 40.5297 |
BPA diluido sin partidas extraordinarias | -0.75367 | -0.86681 | -0.80909 | -0.60402 | -0.70166 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
BPA normalizado diluido | -0.75367 | -0.86681 | -0.80909 | -0.60402 | -0.70166 |
Coste de los ingresos, total | |||||
Beneficio bruto | |||||
Gastos (ingresos) extraordinarios | 0 | 0 |
- Anual
- Trimestral
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
Total Activo Corriente | 367.019 | 435.992 | 9.809 | 10.208 |
Efectivo e inversiones a corto plazo | 363.667 | 434.219 | 9.017 | 8.262 |
Cash | 434.219 | 9.017 | 8.262 | |
Total deudores, neto | 0 | 0.536 | 0.932 | |
Accounts Receivable - Trade, Net | 0 | 0.536 | 0.932 | |
Prepaid Expenses | 3.352 | 1.773 | 0.256 | 1.014 |
Total Assets | 380.183 | 436.054 | 10.676 | 11.164 |
Property/Plant/Equipment, Total - Net | 3.397 | 0.052 | 0.86 | 0.956 |
Property/Plant/Equipment, Total - Gross | 3.46 | 0.077 | 2.309 | 1.976 |
Accumulated Depreciation, Total | -0.063 | -0.025 | -1.449 | -1.02 |
Other Long Term Assets, Total | 9.767 | 0.01 | 0.007 | 0 |
Total Current Liabilities | 15.295 | 6.204 | 4.984 | 1.873 |
Accounts Payable | 3.764 | 0.004 | 3.748 | 0.697 |
Accrued Expenses | 11.102 | 6.049 | 1.046 | 0.905 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.151 | 0.19 | 0.271 | |
Total Liabilities | 17.134 | 6.209 | 10.952 | 2.009 |
Total Long Term Debt | 0.28 | 0 | 5.421 | 0 |
Long Term Debt | 5.421 | 0 | ||
Other Liabilities, Total | 1.559 | 0.005 | 0.547 | 0.136 |
Total Equity | 363.049 | 429.845 | -0.276 | 9.155 |
Preferred Stock - Non Redeemable, Net | 70.363 | 60.933 | ||
Common Stock | 0.041 | 0.04 | 0.021 | 0.021 |
Additional Paid-In Capital | 564.993 | 548.327 | 2.122 | 1.74 |
Retained Earnings (Accumulated Deficit) | -201.985 | -118.522 | -72.782 | -53.539 |
Total Liabilities & Shareholders’ Equity | 380.183 | 436.054 | 10.676 | 11.164 |
Total Common Shares Outstanding | 40.5871 | 39.8445 | 34.7116 | 34.7116 |
Redeemable Preferred Stock | 0 | |||
Efectivo y Equivalentes | 363.667 | |||
Current Port. of LT Debt/Capital Leases | 0.429 | |||
Capital Lease Obligations | 0.28 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Activo Corriente | 321.525 | 367.019 | 388.963 | 412.277 | 432.327 |
Efectivo e inversiones a corto plazo | 316.596 | 363.667 | 385.149 | 409.964 | 429.855 |
Efectivo y Equivalentes | 159.086 | 363.667 | 385.149 | 409.964 | 429.855 |
Prepaid Expenses | 4.929 | 3.352 | 3.814 | 2.313 | 2.472 |
Total Assets | 363.676 | 380.183 | 399.728 | 421.289 | 432.91 |
Property/Plant/Equipment, Total - Net | 6.967 | 3.397 | 3.362 | 0.167 | 0.047 |
Property/Plant/Equipment, Total - Gross | 7.088 | 3.46 | 3.401 | 0.2 | 0.077 |
Accumulated Depreciation, Total | -0.121 | -0.063 | -0.039 | -0.033 | -0.03 |
Other Long Term Assets, Total | 10.075 | 9.767 | 7.403 | 8.845 | 0.536 |
Total Current Liabilities | 15.308 | 15.295 | 12.488 | 13.979 | 14.129 |
Accounts Payable | 5.133 | 3.764 | 3.683 | 5.806 | 7.35 |
Accrued Expenses | 9.746 | 11.102 | 8.376 | 7.744 | 2.735 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.429 | 0.429 | 0.429 | 0.429 | 0.095 |
Other Current Liabilities, Total | 3.949 | ||||
Total Liabilities | 20.08 | 17.134 | 14.556 | 16.275 | 14.426 |
Total Long Term Debt | 0.175 | 0.28 | 0.385 | 0.489 | 0.131 |
Capital Lease Obligations | 0.175 | 0.28 | 0.385 | 0.489 | 0.131 |
Other Liabilities, Total | 4.597 | 1.559 | 1.683 | 1.807 | 0.166 |
Total Equity | 343.596 | 363.049 | 385.172 | 405.014 | 418.484 |
Redeemable Preferred Stock | 0 | ||||
Common Stock | 0.041 | 0.041 | 0.04 | 0.04 | 0.04 |
Additional Paid-In Capital | 570.679 | 564.993 | 558.679 | 553.955 | 551.151 |
Retained Earnings (Accumulated Deficit) | -226.518 | -201.985 | -173.547 | -148.981 | -132.707 |
Total Liabilities & Shareholders’ Equity | 363.676 | 380.183 | 399.728 | 421.289 | 432.91 |
Total Common Shares Outstanding | 40.6566 | 40.5871 | 40.4863 | 40.3253 | 40.2086 |
Inversiones a corto plazo | 157.51 | ||||
Long Term Investments | 25.109 | ||||
Other Equity, Total | -0.606 |
- Anual
- Trimestral
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
Ingresos netos/Línea de salida | -83.463 | -45.74 | -19.243 | -13.731 |
Efectivo de actividades de explotación | -68.101 | -38.289 | -14.249 | -13.19 |
Efectivo de actividades de explotación | 0.051 | 0.202 | 0.429 | 0.431 |
Partidas no monetarias | 19.338 | 7.002 | 0.308 | 0.269 |
Cambios en el capital circulante | -4.027 | 0.247 | 4.257 | -0.159 |
Efectivo de actividades de inversión | -4.923 | 0.61 | -0.353 | -0.653 |
Gastos de capital | -4.923 | -0.031 | -0.353 | -0.653 |
Efectivo procedente de actividades de financiación | 2.472 | 462.881 | 15.357 | 0.001 |
Emisión (retiro) de acciones, neto | 2.753 | 473.235 | 9.44 | 0.001 |
Emisión (amortización) de deuda, neta | -0.281 | 0 | 5.917 | 0 |
Variación neta de la tesorería | -70.552 | 425.202 | 0.755 | -13.842 |
Cash Taxes Paid | 0.274 | 0.047 | ||
Intereses pagados en efectivo | 0.011 | 0.427 | ||
Otras partidas de flujo de caja de inversión, total | 0.641 | |||
Elementos de flujo de caja de financiación | -10.354 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -24.533 | -83.463 | -55.025 | -30.459 | -14.185 |
Cash From Operating Activities | -20.674 | -68.101 | -50.613 | -25.757 | -5.135 |
Cash From Operating Activities | 0.058 | 0.051 | 0.017 | 0.011 | 0.005 |
Non-Cash Items | 5.926 | 19.338 | 8.688 | 4.241 | 1.858 |
Cash Interest Paid | 0 | 0.011 | 0.007 | 0.003 | 0 |
Changes in Working Capital | -2.125 | -4.027 | -4.293 | 0.45 | 7.187 |
Cash From Investing Activities | -183.921 | -4.923 | -0.405 | -0.007 | -0.007 |
Capital Expenditures | -0.589 | -4.923 | -0.405 | -0.007 | -0.007 |
Cash From Financing Activities | 0.08 | 2.472 | 1.948 | 1.509 | 0.778 |
Issuance (Retirement) of Stock, Net | 0.185 | 2.753 | 2.125 | 1.582 | 0.778 |
Net Change in Cash | -204.515 | -70.552 | -49.07 | -24.255 | -4.364 |
Cash Taxes Paid | 0 | 0.274 | 0.274 | 0.274 | |
Financing Cash Flow Items | 0 | 0 | |||
Issuance (Retirement) of Debt, Net | -0.105 | -0.281 | -0.177 | -0.073 | |
Other Investing Cash Flow Items, Total | -183.332 | 0 |
Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
---|---|---|---|---|---|---|
VenBio Partners LLC | Private Equity | 23.8003 | 9699925 | 0 | 2022-12-31 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 14.9987 | 6112789 | 1482504 | 2022-12-31 | LOW |
Lightstone Ventures, L.P. | Investment Advisor | 11.1076 | 4526963 | -194027 | 2022-03-31 | LOW |
Vivo Capital, LLC | Venture Capital | 10.3546 | 4220048 | 0 | 2022-12-31 | MED |
OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 7.0445 | 2871000 | 0 | 2022-12-31 | LOW |
Logos Global Management LLC | Investment Advisor | 5.7651 | 2349600 | -621752 | 2022-12-31 | HIGH |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 3.7051 | 1510050 | 40991 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.4941 | 1424043 | 14289 | 2022-12-31 | LOW |
Eventide Asset Management, LLC | Investment Advisor | 2.2132 | 902000 | 0 | 2022-12-31 | MED |
Cormorant Asset Management, LP | Hedge Fund | 1.5018 | 612079 | -100000 | 2022-12-31 | MED |
Redmile Group, LLC | Investment Advisor/Hedge Fund | 1.4905 | 607470 | -144627 | 2022-12-31 | LOW |
Pons (Jaume) | Individual Investor | 1.3244 | 539746 | -3232 | 2022-12-29 | LOW |
Invus Public Equities Advisors, LLC | Investment Advisor | 1.2268 | 500000 | 0 | 2022-12-31 | LOW |
Morgan Stanley & Co. LLC | Research Firm | 1.171 | 477236 | 90049 | 2022-12-31 | MED |
Federated Hermes MDTA LLC | Investment Advisor/Hedge Fund | 1.1386 | 464029 | -685 | 2022-12-31 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.0117 | 412309 | 18988 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.9656 | 393550 | 8987 | 2022-12-31 | LOW |
DWS Investments UK Limited | Investment Advisor | 0.84 | 342355 | 142 | 2022-12-31 | MED |
Pier Capital, LLC | Investment Advisor | 0.667 | 271848 | -769 | 2022-12-31 | MED |
Randolph (Sophia) | Individual Investor | 0.6631 | 270253 | 44857 | 2022-12-29 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group500K+
Traders
92K+
Clientes activos mensualmente
$53M+
Volumen mensual de inversión
$30M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
ALX Oncology Holdings Inc. Company profile
Sobre ALX Oncology Holdings Inc
ALX Oncology Holdings Inc. es una empresa de inmuno-oncología en fase clínica. La empresa se centra en permitir a los pacientes luchar contra el cáncer mediante el desarrollo de terapias que bloquean la vía del punto de control del clúster de diferenciación 47 (CD47) y tienden un puente entre el sistema inmunitario innato y el adaptativo. La empresa está desarrollando un inhibidor de puntos de control diseñado para tener afinidad por CD47 y evitar las limitaciones causadas por las toxicidades hematológicas inherentes a otros enfoques de bloqueo de CD47. Su principal candidato a producto, el ALX148, es una terapia de bloqueo de CD47. ALX148 es una proteína de fusión que combina un dominio de unión a CD47 con su fragmento inactivado cristalizable (Fc). El dominio de unión a CD47 de ALX148 es un dominio extracelular mejorado por afinidad de la proteína reguladora de señales alfa (SIRPa), una proteína que es el receptor natural de CD47 que se encuentra en las células mieloides. Sus programas se centran en atacar a CD47 en varias indicaciones oncológicas.
Industry: | Bio Therapeutic Drugs |
323 Allerton Avenue
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 500.000 traders de todo el mundo que eligen operar con Capital.com